Read + download the full collection of #ASGCTBreakthroughs24 abstracts ahead of our inaugural muscular dystrophy conference Nov. 19-20.
Monday, November 4 | 9 a.m.–5 p.m. | The Westin City Center, Washington, D.C.
The goal of this program is to explore solutions to challenges experienced both by global regulators and by sponsors developing gene therapies across established and emerging markets. Scheduled topics include identifying differences in regulatory requirements and areas of opportunity for greater convergence of regulatory frameworks.
Keynote Speaker: Peter Marks, M.D., Ph.D. Director of FDA CBER
Peter Marks, M.D., Ph.D., Director of the Center for Biologics Evaluation and Research (FDA CBER), opens the first day of the 2019 Policy Summit with potential areas for increased convergence of global regulatory policies for gene therapies, and the significance of striving toward this goal, as part of a session on the challenges and opportunities for developing multinational programs.
Regulators from Europe, Japan, and the United States will provide updates and discuss difficulties and opportunities in enabling sustainable and adaptable regulatory frameworks for gene therapies:
November 19-20, 2024 | Chicago, IL
© 2000-2024 All rights reserved. American Society of Gene & Cell Therapy.
Kentico CMS Development by Reason One | Powered by Kentico